Tesamorelin
Symbol Ts · MW 5136 Da
Stabilized GHRH analog targeting visceral adipose tissue.
- Discovered
- 2010
- Half-life
- 38 minutes
- Approval
- FDA-approved (Egrifta)
Quick facts
- Category
- Hormone
- Route
- Injectable
- Molecular weight
- 5136 Da
- Half-life
- 38 minutes
- Discovered
- 2010
- Approval status
- FDA-approved (Egrifta)
Reported effects
- Visceral fat reduction
- Lipid profile
- Cognition support
Overview
Tesamorelin is a synthetic growth hormone-releasing hormone analog used for a specific medical purpose: reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It stimulates natural growth hormone release, which can influence fat metabolism and body composition. Tesamorelin is sometimes discussed in the broader weight loss and hormone peptide space, but its approved use is more specific than general fat loss. Its purpose is to target visceral abdominal fat through growth hormone-releasing pathways. As a hormone peptide, Tesamorelin is best understood as a medically established GHRH analog with a focused role in metabolic and body-composition support.
Evidence context
Tesamorelin evidence summary
Human clinical evidence
Tesamorelin has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Tesamorelin may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Tesamorelin as FDA-approved (Egrifta). The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 1.4 mg for EGRIFTA SV or 1.28 mg for EGRIFTA WR; older 2 mg vial formulation may use 2 mg
- Typical Frequency
- Once daily
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Tesamorelin.
Internal links
Related peptides
Frequently asked questions
What category is Tesamorelin in?
Tesamorelin is listed in the Hormone category on Peptidic.
What route is Tesamorelin associated with?
Tesamorelin is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Tesamorelin approved?
Peptidic lists the approval status for Tesamorelin as: FDA-approved (Egrifta). Approval details can vary by indication and jurisdiction.
Interested in Tesamorelin?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01